Rationale: The precise role of each nitric oxide synthase isoforms (NOS) in the pathobiology of asthma is not well established. Objective: To investigate the contribution of constitutive (cNOS) and inducible (iNOS) isoforms to lung mechanics, inflammatory and remodeling responses in an experimental model of chronic allergic pulmonary inflammation. Methods:
fibers deposition in airway wall. In order to achieve these objectives guinea pigs with chronic allergic pulmonary inflammation were chronically treated with either a false substrate of NOS (L-NAME) or a specific and highly selective iNOS inhibitor (1400W).
Methods
All guinea pigs received humane care in compliance with the "Guide for care and use of laboratory animals" (NIH publication 85-23, revised 1985) , and all experiments described in this study were approved by the institutional review board of University of São Paulo (São Paulo, Brazil).
Induction of chronic allergic pulmonary inflammation: Male Hartley guinea pigs, weighing 300-400 g, were placed in a plexiglass box (30 x 15 x 20 cm) coupled to an ultrasonic nebulizer (Soniclear, São Paulo, Brazil). A solution of ovalbumin (OVA, Grade V, Sigma Chemical Co., Saint Louis, MO) diluted in 0.9% NaCl (normal saline) was prepared. The animals received seven inhalations during four weeks with increasing concentrations of OVA (1~5 mg/mL) in order to counteract tolerance ( Figure 1 ). Control animals received aerosolized normal saline. The solution was continuously aerosolized into the environment until respiratory distress (sneezing, coryza, cough or retraction of the thoracic wall) occurred, or until 15 minutes had elapsed, as previously described. The time that animals were in contact to aerosol was denominated inhalation time, as previously described (4, 6, 12) . The observer who made the decision to withdraw the guinea pig from the inhalation box was blinded to the treatment status of the animal.
Chronic L-NAME treatment: Chronic L-NAME treatment (60 mg/kg/animal/day) was performed as previously described (6) . Briefly, guinea pigs received L-NAME dissolved in drinking water ad libitum (OVA-L or NS-L groups, see below), beginning 24 hours after the 4 th inhalation of either OVA or normal saline. Control animals received only sterile drinking water.
1400W treatment: Each animal received 1400W (2mg/kg/animal/day, i.p.) (13) for four days (OVA-W or NS-W groups, see below), beginning 30 minutes before the 7th inhalation of either ovalbumin or normal saline. Control guinea pigs received the same volume of i.p. normal saline. The choice for a shorter treatment period for 1400W in comparison to L-NAME was based on the knowledge that the first drug could have some toxic effects when applied at high doses and for prolonged period (13) .
Experimental groups: a) animals received aerosolized saline, and vehicle of both L-NAME and 1400W (NS, n=9); b) animals received aerosolized ovalbumin and vehicle of both L-NAME and 1400W (OVA, n=9); c) animals received aerosolized saline, and 1400W treatment (NS-W, n=8). d) animals received aerosolized ovalbumin, and 1400W treatment (OVA-W, n=8). e) animals received aerosolized saline, and L-NAME treatment (NS-L, n=8). f) animals received aerosolized ovalbumin, and L-NAME treatment (OVA-L, n=8).
Concentration of exhaled nitric oxide (E NO ): Seventy-two hours after the seventh inhalation, the animals were anesthetized with pentobarbital sodium (50 mg.kg -1 , i.p.).
They were then tracheostomized and mechanically ventilated at 60 breaths/min with a tidal volume of 8 ml.kg -1 using a Harvard 683 ventilator (Harvard Apparatus, South Natick, MA). E NO levels were measured at the expiratory port of the ventilator using a Mylar Bag (3-6) for five minutes (Figure 1 ). Concentrations of E NO were measured by chemiluminescence using a fast-responding analyzer (NOA 280, Sievers
Instruments, Inc., Boulder, CO). Prior to each measurement, the analyzer was calibrated with a certified 47 parts per billion (ppb) NO source (White Martins, São
Paulo, Brazil) and zero NO filter (Sievers Instruments, Inc.). In order to avoid environment contamination, a NO filter was attached to the breathing circuit.
Pulmonary mechanics evaluation: Tracheal pressure (Ptr) was measured with a 142PC05D differential pressure transducer (Honeywell, Freeport, IL) connected to a side tap in the tracheal cannula. Airflow (V & ) was determined using a pneumotachograph (Fleisch 4-0, Richmond, VA) connected to the tracheal cannula and to a Honeywell 163PC01D36 differential pressure transducer, as previously described (5) (6) 12) . Changes in lung volume (V) were determined by digital integration of the airflow signal. Nine to ten respiratory cycles were averaged to provide one data point. Respiratory system elastance (Ers) and resistance (Rrs) were obtained using the equation of motion of the respiratory system.
where t is time, Ers is respiratory system elastance and Rrs is respiratory system resistance.
After baseline measurements of E NO , Ptr and V & , we performed two one-minute challenges with either aerosolized ovalbumin (30 mg.ml Still under anesthesia and after the measurements of pulmonary mechanics after the challenge, the anterior chest wall was opened and lungs were washed with heparinized saline solution (1:40) . Guinea pigs were then exsanguinated, a positive end-expiratory pressure of 5 cm H 2 O was applied to the respiratory system, the airways were occluded at the end of expiration and the lungs were removed en bloc.
Morphometric studies: The left lung was fixed with 4% buffered paraformaldehyde for 24 h and then transferred to 70% ethanol. Sections representing peripheral areas of the lung were cut and processed for paraffin embedding. Histological sections (5 µm in thickness) were cut and stained with hematoxylin and eosin and were evaluated by researchers blinded to the protocol design. We evaluated edema formation and inflammatory cell infiltrates around the airway (between the bronchial epithelium and the adventitia) employing an integrating eyepiece (10 4 µm 2 of total area) (4-6, 12).
Ten to twenty fields were analyzed per lung at a magnification of x1,000.
Peribronchial edema was quantified in randomly selected transversely sectioned noncartilaginous airways. ) in a nine-ten distal airways/lung, using polarized light for collagen evaluation, at a magnification of x200, in an image analysis system (Image J 1.30v) (6) . The collagen or elastic content (%) was expressed as a relation between the quantity of collagen or elastic fibers in a specific frame and the total area of the frame.
Statistical analysis: Values are expressed as means ± SE. Statistical analysis was performed using SigmaStat software (SPSS Inc, Chicago, IL). Data were evaluated by two-way analysis of variance and multiple comparisons were made using Tukey Test. A p value of less than 0.05 was considered significant.
Results
Inhalation time: No differences were observed among the groups during the inhalations 1 to 4. The saline-exposed animals stayed 900 seconds in all inhalations.
At fifth, sixth, and seventh inhalations, ovalbumin-exposed animals showed lower values of inhalation time [7 th inhalation (mean ± SEM: 300.2 ± 38.0 sec)] compared with normal saline-exposed animals (900.0 ± 0 sec) (p<0.001). Neither L-NAME nor 1400W treatments affected the time during which the animals could stay in contact with the antigen before the onset of respiratory symptoms [7th inhalation (OVA-L:
343.0 ± 112.3 sec; OVA-W: 311.1 ± 142.1 sec).
Concentration of E NO : Figure 2 shows the levels of E NO measured 72 hours after the seventh inhalation of either saline or ovalbumin solution. Values of E NO were higher in the OVA group compared with NS group (p=0.001). L-NAME treatment reduced E NO in both ovalbumin and saline-exposed animals (p<0.01). In contrast, 1400W
treatment reduced E NO only in ovalbumin-exposed guinea pigs (p<0.01).
Respiratory mechanics evaluation: Figures 3A and 3B show baseline (pre-ovalbumin challenge) values of Rrs and Ers, respectively. There were no significant differences in baseline values of Rrs and Ers between OVA and NS groups. Both L-NAME and 1400W treatments increased baseline values of Rrs in both ovalbumin and salineexposed guinea pigs (p<0.05). In addition, 1400W treatment resulted in baseline values of Rrs greater than L-NAME treatment (p<0.001). In contrast, both L-NAME and 1400W treatments reduced baseline values of Ers, and these differences were statistically significant only in the saline-exposed animals (p<0.05) ( Figure 3B ). We did not observe significant differences in Ers values when L-NAME and 1400W
treatments were compared.
After ovalbumin challenge or normal saline inhalation, we evaluated the percentage of maximal increase of both Rrs (%Rrs) ( Figure 3C ) and Ers (%Ers) ( Figure 3D ). The group inhaled with ovalbumin showed greater values of %Rrs and %Ers compared with saline-exposed animals (p<0.001). Considering ovalbumin-exposed guinea pigs, L-NAME treatment increased %Rrs (p<0.01). In contrast, 1400W treatment resulted in lower maximal response of Rrs induced by ovalbumin challenge (p<0.01).
Ovalbumin-exposed guinea pigs that were treated with L-NAME (OVA-L group)
showed greater values of %Ers compared with OVA-W group (p<0.05).
Peribronchial edema index: Figure 4A shows mean (± SE) values of edema index.
We noticed that chronically ovalbumin-exposed guinea pigs showed greater values of edema index compared with normal saline-exposed (p<0.01). Only L-NAME treatment attenuated peribronchial edema formation (p<0.01).
Inflammatory cell infiltrates: Figure 4B and 4C show the numbers of mononuclear cells (MN) (B) and eosinophils (C) in the wall of distal (non-cartilaginous) airways of the six experimental groups studied. There were no significant differences among the normal saline-exposed groups (NS, NS-L, and NS-W). The number of MN and eosinophils in ovalbumin-exposed was greater than that observed in saline-exposed guinea pigs (p<0.001). In ovalbumin-exposed animals, both L-NAME and 1400W treatments (p<0.05) reduced the number of MN in airways. However, only 1400W treatment attenuated the eosinophilic infiltration around airways (p<0.001 compared with OVA and OVA-L groups).
Considering the number of cells positive for nNOS ( Figure 4D ) and iNOS ( Figure 4E ), OVA-exposed guinea pigs showed an increase in both nNOS and iNOS-positive eosinophils around airways (p<0.01) compared with normal saline-exposed animals.
L-NAME treatment attenuated these responses (p<0.05) and 1400W reduced only iNOS-positive eosinophils in sensitized animals (p<0.001) compared with animals that received vehicle. stained with Picrossirius and observed using polarized light. In saline-exposed guinea pigs there was a weak red-orange birefringence of peribronchial interstitium in tissue sections ( Figure 6B ) coincident with the maintenance of the peribronchiolar extracellular matrix architecture ( Figure 6A ). In contrast, in ovalbumin-exposed animals there was a diffuse increase of birefringence ( Figure 6E ) in peribronchiolar ECM seen in H&E preparations ( Figure 6D ). Figure 6H shows that chronic L-NAME treatment increased collagen deposition around the distal airway wall without interfering with elastic content ( Figure 6I ). Figures 6L and M show that chronic 1400W treatment decreased both collagen and elastic fibers deposition around the distal airway wall, with a reduction in inflammatory cell infiltrate ( Figure 6J ).
Quantification of airway remodeling: Measurements of airway remodeling are shown in Figure 7 . Airway wall area and the collagen and elastic airway content were similar in all saline-exposed animals. Airway wall area was significantly higher in ovalbuminexposed animals ( Figure 7A ) compared with saline-exposed groups (p<0.05). Neither L-NAME nor 1400W treatments affected airway wall area. Regarding collagen content ( Figure 7B ), ovalbumin-exposed animals also showed greater values of collagen % compared with saline-exposed animals (p<0.05). L-NAME-treatment resulted in an increase in collagen deposition in airway wall and treatment with 1400W resulted in a decrease in this response (p<0.05 compared with OVA group).
Considering elastic airway fibers ( Figure 7C ), we observed that ovalbumin-exposed animals had an increase in the content of these fibers compared with saline-exposed groups (p<0.05). Only 1400W treatment reduced this response (p<0.05 compared with OVA and OVA+L groups).
Discussion
The role of NO in asthmatics and in animal models of allergic airway inflammation as well as the relative contribution of each of NOS isoforms for the production of this molecule remains incompletely understood. In the present study, we intended to clarify the importance of cNOS and iNOS isoforms in an experimental model of chronic allergic airway inflammation. In this regard, we used L-NAME, a non-selective false substrate that inhibits NO produced by all NOS isoforms and 1400W, an iNOS inhibitor. Since 1400W is specific and highly selective for iNOS inhibition, the differences observed among the experimental groups would probably be related to the absence of cNOS-derived NO in the experimental group that received L-NAME treatment. Previous studies had demonstrated that 1400W is one of the most selective inhibitors of iNOS. In addition, 1400W presents an in vivo selectivity of at least 100-fold greater than others NOS inhibitors such as aminoguanidine (13, 16) .
Other iNOS inhibitors are at best 30-fold more potent against iNOS than eNOS whereas 1400W is over 5000-and 200-fold more potent against iNOS than eNOS and nNOS, respectively (13, 16) .
It is important to emphasize that the differences in the dose schedules of 1400W and L-NAME used in the present study were related to their pharmacokinetics as previously determined (13, 17) . Since high doses of 1400W (50 mg/kg i.p.) can cause some toxic effects (13, 16) related to nervous and cardiovascular system, including induction of convulsions, we used a lower dose (2 mg/kg i.p. for four days). That choice of dose was based on a study that found a significant reduction in LPS-induced vascular leakage using doses of 1400W within the range of 1-5 mg/kg (13) .
Although the effects of these treatments may be influenced by the continuous or pulsatile NOS inhibition, their selectivity were demonstrated by analyzing the results of E NO and the immunohistochemical studies detecting eosinophils positive for nNOS and iNOS (Figures 2 and 4 ).
E NO has been considered a useful marker of airway inflammation in human asthma (1, 2) and in animal models of allergic inflammation (3) (4) (5) (6) . In the present study, ovalbumin-exposed animals presented an increase in E NO compared with salineexposed ones. In experimental models of pulmonary inflammation, the concentrations of NO detected in the exhaled air have been predominantly used to evaluate the efficacy of tested treatments. Noteworthy, the values of E NO observed in saline-exposed animals (20 ppb) are similar to the values found in other studies with guinea pigs (3). Interestingly, all animals receiving L-NAME presented a significant reduction in the concentrations of E NO . In contrast, 1400W reduced the concentrations of E NO only in ovalbumin-exposed guinea pigs. Evaluating the number of eosinophils positive for NOS, we observed that L-NAME treatment reduced the number of eosinophils positive for both NOS enzymes. However, 1400W reduced only the iNOS-positive eosinophils, without modifying the number of cells positive for nNOS. Despite the fact that these results confirmed the effectiveness of both treatments in E NO reduction, they also suggest that 1400W treatment had high selectivity to iNOS isoform that are present mainly in inflammatory situations.
We had previously studied this model of chronic allergic airway inflammation in guinea pigs (4) (5) (6) 12) . Chronically ovalbumin-exposed guinea pigs presented hyperresponsiveness to methacholine, an intense bronchoconstriction after antigen challenge, and an increase in the number of eosinophils and CD4+ lymphocytes in both bronchoalveolar lavage and lung tissues. In fact, in this experimental model, eosinophils comprise 70-75% of inflammatory cells in bronchoalveolar lavage fluid (12) . Recently, we have also demonstrated that, in this experimental model, there is an increase in the number of MN and eosinophils positive for iNOS around airways of ovalbumin-exposed guinea pigs (5) . In addition, we observed an increase in the content of collagen fibers around airway wall (6) . In the present study, we observed that NO produced by iNOS increases both collagen and elastic fibers content in airway wall. Additionally, it contributes to bronchoconstriction and amplifies inflammatory responses.
The inhalation time is the time that the animals stayed in contact with antigen without respiratory distress symptoms and reflects an acute response to antigen exposure.
OVA-exposed animals stayed lower time in contact to antigen after fifth inhalation compared with saline-exposed animals (4-6, 12) and neither L-NAME nor 1400W treatments influenced the inhalation time in the seventh inhalation compared with vehicle-treated animals. These results suggested that NO did not interfere with acute responses to antigen exposure. Although NO has been considered one of the mediators that influence airway smooth muscle responses (2, 18), other factors are involved in acute responses to antigen contact, including activation of different pathways that control airway smooth muscle contraction and mast cell degranulation (19) .
Considering saline-exposed animals, we observed that both L-NAME and 1400W
treatments increased the resistance of respiratory system. Since the role of iNOS is more pronounced in inflammatory situations, few studies have evaluated the effects of iNOS inhibition on physiological situations. We have previously shown that there is a basal expression of iNOS in resident cells around airways in guinea pigs not exposed to an inflammatory stimulus (5). In addition, Guo et al. (20) showed that iNOS is continuously produced by airway epithelium in normal humans. Interestingly, the effects of 1400W treatment in the increase of Rrs were more pronounced than those observed with L-NAME treatment, regardless of chronic ovalbumin exposure.
These data are in agreement with previous studies that suggested the presence of a cNOS bronchodilation effect (2, 9, 18). In addition, we suggest that NO produced by iNOS can also contribute to the control of airway smooth muscle responses.
In contrast to the increase in Rrs observed with NOS inhibition, both L-NAME and 1400W treatments decreased baseline values of Ers in saline-exposed guinea pigs, suggesting an effect of NO on small airways and/or distal airspaces. However, it was previously shown that the effects of NO are more pronounced in proximal airways since there is a decrease in nitrergic nerves towards distal airways (18) . In this context, Lilly et al. (21) showed that the vasointestinal peptide (VIP) injection in isolated guinea pig trachea has the capacity to relax whole lungs in part by stimulating the generation of NO due to nNOS activation. (iNOS) (24) . In the present study we also observed these divergences since L-NAME partially reduced the inflammation but induced the bronchoconstriction. However, the evaluation of iNOS effects by 1400W treatment showed a similar effect on the attenuation of both inflammatory and mechanical parameters.
Many studies have focused on the role of NO in the modulation of airway smooth muscle contraction in different models of experimental pulmonary allergic inflammation (5, 6, (25) (26) (27) . It has been previously shown that NO mainly derived from constitutive isoforms of NOS attenuates bronchoconstriction induced by allergen in sensitized experimental animals (2, 9, 25) . In contrast, others have observed that nNOS-derived NO could contribute to airway constriction (28) . Our results suggest a protective effect of NO derived from cNOS, since the increase in Rrs induced by antigen challenge was significantly greater in guinea pigs treated with L-NAME but not in the experimental group that received 1400W ( Figure 3 ). In addition, iNOS isoform contributed to airway constriction, mainly in the proximal airways, since the group of guinea pigs that received 1400W presented an increase in Rrs induced by ovalbumin challenge lower than that seen in the group that did not receive NOS antagonists. It has been previously suggested that iNOS could contribute to antigeninduced airway constriction. Several mechanisms reported in the literature intended to explain how NO could interfere in airway tone (2) and the ability of NO to control airway tone could be related to both GMPc-dependent and independent mechanisms (29-31).
Considering the peribronchial edema evaluation, we showed that only L-NAME treatment was involved in the attenuation of this response. The effects of NO reducing peribronchial edema could be an effect of NO-inhibition reducing airway inflammation. In this context, it was expected an effect of 1400W treatment diminishing edema index since this treatment was more effective in reducing airway inflammation than L-NAME treatment. Therefore, the effects of L-NAME in edema formation could be attributed to other effects of NO, including vasodilation and modulation of capillary leakage (32) . There are several studies showing that NO plays a role as a vasodilator and this function is probably derived from NO produced by constitutive isoforms (2, 6, 9).
The precise role of NO in airway inflammation remains unclear and depends on experimental protocol and the inhibitors used. We observed that L-NAME treatment diminished only MN cells in airway wall and specific iNOS inhibition with 1400W
reduced both eosinophilic and MN cell recruitment, confirming previous reports suggesting a pro-inflammatory iNOS effect (25, 33) . Although we have recently observed that acute treatment with L-NAME inhibits the eosinophilic recruitment in guinea pigs with chronically allergic pulmonary inflammation (5-6), we did not obtain the same results after chronic L-NAME treatment (6) . Regarding this issue, Birrel et al. (34) showed that L-NAME but not 1400W acute treatments attenuated eosinophilic recruitment. These differences could be related to a compensatory increase in iNOS (35) , no effects on eosinophilopoiesis (36) or differences in apoptosis modulation (37). Taylor et al. (37) suggested that NO could have different effects on inflammatory cell apoptosis (anti-and pro-apoptotic properties), depending on the concentration, flux and source of NO.
There are a very small number of previous studies comparing LNAME and 1400W in models of airway or pulmonary inflammation and no previous study evaluating airway Airway remodeling, characterized by structural changes in airway wall, has an important clinical significance by contributing to the irreversibility of lung function alterations observed in asthmatic patients (11) . Our study showed some important results concerning airway-remodeling process. First, NO derived from cNOS protected against airway collagen deposition without interfering with elastic fiber content. Second, the specific inhibition of iNOS by 1400W treatment decreased both collagen and elastic fiber content in the airway wall. The relevance of iNOS activation to the airway remodeling process was poorly defined and other authors have been unable to observe the same result (10). These differences could be related to the use of genetically NOS-deficient mice. We suggest that conflicting results have been described using NOS knockout mice and the maturation and development of the innate immune system may be important for the expression of the allergic response.
The present study evaluated whether NO pathway are involved in airway remodeling Considering elastic fibers, we did not find other studies that evaluated the effects of iNOS derived NO on elastic fiber deposition in asthma models. One possible 22 explanation for the inhibition of collagen and elastic fiber content in airways may be related to the effects of NO on the modulation of inflammatory response, modifying cytokine or chemokine profiles and neutrophilic responses (8, 33) . However, more studies are needed in order to clarify these unsolved questions.
In conclusion, the nonspecific inhibition of NO production by L-NAME treatment in guinea pigs with allergen-induced chronic pulmonary inflammation potentates the bronchoconstiction and the airway remodeling, particularly the airway collagen deposition. In contrast, blockage of iNOS-derived NO attenuates antigen-induced airway constriction, inflammatory and remodeling processes reducing both collagen and elastic fiber deposition. *p=0.001 compared with saline-exposed animals that received vehicle (NS group) and **p<0.01 compared with saline and ovalbumin-exposed animals that received vehicle (NS and OVA groups, respectively). ). *p<0.01 compared with saline-exposed guinea pigs, respectively; **p<0.05 compared with ovalbumin-exposed animals that received vehicle (OVA group). †p<0.001 compared with ovalbumin-exposed guinea pigs that received vehicle or L-NAME (OVA and OVA-L groups). *p<0.05 compared with saline-exposed animals; **p<0.05 compared with other two ovalbumin-exposed groups (OVA and OVA-W groups), and †p<0.05 compared with other two ovalbumin-exposed animals (OVA and OVA-L groups). 
